366 related articles for article (PubMed ID: 27161449)
1. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
[TBL] [Abstract][Full Text] [Related]
2. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
Parakh S; Nguyen R; Opie JM; Andrews MC
Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.
Naidoo J; Schindler K; Querfeld C; Busam K; Cunningham J; Page DB; Postow MA; Weinstein A; Lucas AS; Ciccolini KT; Quigley EA; Lesokhin AM; Paik PK; Chaft JE; Segal NH; D'Angelo SP; Dickson MA; Wolchok JD; Lacouture ME
Cancer Immunol Res; 2016 May; 4(5):383-9. PubMed ID: 26928461
[TBL] [Abstract][Full Text] [Related]
4. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
5. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
Rofe O; Bar-Sela G; Keidar Z; Sezin T; Sadik CD; Bergman R
Clin Exp Dermatol; 2017 Apr; 42(3):309-312. PubMed ID: 28211077
[TBL] [Abstract][Full Text] [Related]
6. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL
J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
9. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.
Carlos G; Anforth R; Chou S; Clements A; Fernandez-Peñas P
Melanoma Res; 2015 Jun; 25(3):265-8. PubMed ID: 25831416
[TBL] [Abstract][Full Text] [Related]
10. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
11. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
[TBL] [Abstract][Full Text] [Related]
12. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Hwang SJE; Fernández-Peñas P
Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
Morris LM; Lewis HA; Cornelius LA; Chen DY; Rosman IS
J Cutan Pathol; 2020 Aug; 47(8):742-746. PubMed ID: 32196722
[TBL] [Abstract][Full Text] [Related]
14. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
[No Abstract] [Full Text] [Related]
15. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab.
Sundaresan S; Nguyen KT; Nelson KC; Ivan D; Patel AB
Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469720
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
[TBL] [Abstract][Full Text] [Related]
17. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.
Hwang SJ; Carlos G; Chou S; Wakade D; Carlino MS; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):413-6. PubMed ID: 27031539
[TBL] [Abstract][Full Text] [Related]
18. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
Trinidad C; Nelson KC; Glitza Oliva IC; Torres-Cabala CA; Nagarajan P; Tetzlaff MT; Ivan D; Hwu WJ; Prieto VG; Curry JL; Aung PP
J Cutan Pathol; 2018 Jul; 45(7):504-507. PubMed ID: 29633300
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
20. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
